Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Effect of Bisoprolol on the Level of Dabigatran.

Nehaj F, Sokol J, Ivankova J, Mokan M, Mokan M.

Am J Ther. 2018 Jul 12. doi: 10.1097/MJT.0000000000000786. [Epub ahead of print]

PMID:
30074534
2.

The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation.

Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M.

Am J Ther. 2017 Apr 25. doi: 10.1097/MJT.0000000000000599. [Epub ahead of print]

PMID:
28452843
3.

Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.

Brunetti L, Chen C, White J.

Consult Pharm. 2014 Mar;29(3):169-78. doi: 10.4140/TCP.n.2014.169. Review.

PMID:
24589766
4.

Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.

Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A, Yoshida T, Masutomi T, Kambara T, Inoue Y, Nakashima Y, Asano H, Sakai K.

J Arrhythm. 2017 Dec;33(6):619-623. doi: 10.1016/j.joa.2017.07.013. Epub 2017 Oct 12.

5.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

PMID:
23922182
6.

Effect of selective beta-blockade with bisoprolol in the treatment of recent-onset atrial fibrillation.

Negreva MN, Penev AP.

Folia Med (Plovdiv). 2012 Apr-Jun;54(2):27-31.

PMID:
23101282
7.

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L.

Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17.

PMID:
17950801
8.

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.

Jain R, Fu AC, Lim J, Wang C, Elder J, Sander SD, Tan H.

J Manag Care Spec Pharm. 2018 Jan;24(1):73-82. doi: 10.18553/jmcp.2018.24.1.73.

9.

Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.

Fieland D, Taylor M.

Ann Pharmacother. 2012 Jan;46(1):e3. doi: 10.1345/aph.1Q474. Epub 2011 Dec 27.

PMID:
22202498
10.

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C, Schein JR, Lefebvre P, Peterson ED.

J Manag Care Spec Pharm. 2017 Sep;23(9):980-988. doi: 10.18553/jmcp.2017.23.9.980.

11.

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.

Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A.

J Thromb Haemost. 2011 Nov;9(11):2168-75. doi: 10.1111/j.1538-7836.2011.04498.x.

12.

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation.

Choi JC, Dibonaventura MD, Kopenhafer L, Nelson WW.

Patient Prefer Adherence. 2014 Feb 7;8:167-77. doi: 10.2147/PPA.S56187. eCollection 2014.

13.

Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.

Mochalina N, Juhlin T, Platonov PG, Svensson PJ, Wieloch M.

Thromb Res. 2015 Jun;135(6):1070-4. doi: 10.1016/j.thromres.2015.03.015. Epub 2015 Mar 19.

PMID:
25842008
14.

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.

Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30.

PMID:
25359164
15.

Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.

Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.

Circulation. 2015 Sep 29;132(13):1252-60. doi: 10.1161/CIRCULATIONAHA.115.015710. Epub 2015 Jul 21.

16.

Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation.

Janssen AM, van de Kerkhof D, Szabó B, Durian MF, van der Voort PH.

Neth J Med. 2016 Aug;74(7):313-5.

17.

Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin.

Watanabe T, Shinoda Y, Ikeoka K, Inui H, Fukuoka H, Sunaga A, Kanda T, Uematsu M, Hoshida S.

Heart Vessels. 2017 Mar;32(3):326-332. doi: 10.1007/s00380-016-0871-5. Epub 2016 Jul 12.

18.

The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.

Chang YT, Hu YF, Liao JN, Chern CM, Lin YJ, Chang SL, Wu CH, Sung SH, Wang KL, Lu TM, Chao TF, Lo LW, Hsu LC, Chung CP, Chang PM, Hsu WH, Chiou CW, Chen SA.

Blood Coagul Fibrinolysis. 2016 Jun;27(4):389-95. doi: 10.1097/MBC.0000000000000558.

PMID:
26991859
19.

Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.

Stöllberger C, Finsterer J.

Herz. 2015 Apr;40 Suppl 2:140-5. doi: 10.1007/s00059-014-4188-9. Epub 2015 Jan 25. Review.

PMID:
25616425
20.

Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.

Lauffenburger JC, Rhoney DH, Farley JF, Gehi AK, Fang G.

Pharmacotherapy. 2015 Jun;35(6):560-8. doi: 10.1002/phar.1597. Epub 2015 Jun 4.

Supplemental Content

Support Center